Pharmaceutical company decision-makers are in disagreement about the merits of calculating the value of technology solutions. Some deem the demonstration of ROI unnecessary because Web-enabling processes is inevitable and desirable, while others view eHealth as any other initiative that requires metrics to demonstrate its value to the enterprise. This Brief analyzes the ROI conundrum and explains why eHealth performance indicators should be established. This analysis provides: * Case studies illustrating how pharmaceutical companies and vendors can tackle the problems associated with measuring ROI * Survey data revealing opinions of pharmaceutical eBusiness executives, helping companies benchmark their own approaches to ROI * Recommendations on how companies should design ROI models that will best serve them in the future
